160 related articles for article (PubMed ID: 29512887)
1. Opioid and nondopamine reward circuitry and state-dependent mechanisms.
Fujita M; Ide S; Ikeda K
Ann N Y Acad Sci; 2019 Sep; 1451(1):29-41. PubMed ID: 29512887
[TBL] [Abstract][Full Text] [Related]
2. A ghrelin receptor (GHS-R1A) antagonist attenuates the rewarding properties of morphine and increases opioid peptide levels in reward areas in mice.
Engel JA; Nylander I; Jerlhag E
Eur Neuropsychopharmacol; 2015 Dec; 25(12):2364-71. PubMed ID: 26508707
[TBL] [Abstract][Full Text] [Related]
3. There and back again: a tale of norepinephrine and drug addiction.
Weinshenker D; Schroeder JP
Neuropsychopharmacology; 2007 Jul; 32(7):1433-51. PubMed ID: 17164822
[TBL] [Abstract][Full Text] [Related]
4. Brain mechanisms of drug reward and euphoria.
Wise RA; Bozarth MA
Psychiatr Med; 1985; 3(4):445-60. PubMed ID: 2893431
[TBL] [Abstract][Full Text] [Related]
5. Serotonin-1A receptor dependent modulation of pain and reward for improving therapy of chronic pain.
Haleem DJ
Pharmacol Res; 2018 Aug; 134():212-219. PubMed ID: 29969666
[TBL] [Abstract][Full Text] [Related]
6. Morphine reward in dopamine-deficient mice.
Hnasko TS; Sotak BN; Palmiter RD
Nature; 2005 Dec; 438(7069):854-7. PubMed ID: 16341013
[TBL] [Abstract][Full Text] [Related]
7. Expression of immediate early genes in brain reward circuitries: Differential regulation by psychostimulant and opioid drugs.
Bisagno V; Cadet JL
Neurochem Int; 2019 Mar; 124():10-18. PubMed ID: 30557593
[TBL] [Abstract][Full Text] [Related]
8. HIV Infection and Neurocognitive Disorders in the Context of Chronic Drug Abuse: Evidence for Divergent Findings Dependent upon Prior Drug History.
Illenberger JM; Harrod SB; Mactutus CF; McLaurin KA; Kallianpur A; Booze RM
J Neuroimmune Pharmacol; 2020 Dec; 15(4):715-728. PubMed ID: 32533296
[TBL] [Abstract][Full Text] [Related]
9. Distinct Roles of Opioid and Dopamine Systems in Lateral Hypothalamic Intracranial Self-Stimulation.
Ide S; Takahashi T; Takamatsu Y; Uhl GR; Niki H; Sora I; Ikeda K
Int J Neuropsychopharmacol; 2017 May; 20(5):403-409. PubMed ID: 28031268
[TBL] [Abstract][Full Text] [Related]
10. Endogenous opioids and addiction to alcohol and other drugs of abuse.
Gianoulakis C
Curr Top Med Chem; 2004; 4(1):39-50. PubMed ID: 14754375
[TBL] [Abstract][Full Text] [Related]
11. The neurobiology of addictive disorders.
Ross S; Peselow E
Clin Neuropharmacol; 2009; 32(5):269-76. PubMed ID: 19834992
[TBL] [Abstract][Full Text] [Related]
12. Involvement of the brain histaminergic system in addiction and addiction-related behaviors: a comprehensive review with emphasis on the potential therapeutic use of histaminergic compounds in drug dependence.
Brabant C; Alleva L; Quertemont E; Tirelli E
Prog Neurobiol; 2010 Nov; 92(3):421-41. PubMed ID: 20638439
[TBL] [Abstract][Full Text] [Related]
13. Hypothesizing That Neuropharmacological and Neuroimaging Studies of Glutaminergic-Dopaminergic Optimization Complex (KB220Z) Are Associated With "Dopamine Homeostasis" in Reward Deficiency Syndrome (RDS).
Blum K; Febo M; Fried L; Li M; Dushaj K; Braverman ER; McLaughlin T; Steinberg B; Badgaiyan RD
Subst Use Misuse; 2017 Mar; 52(4):535-547. PubMed ID: 28033474
[TBL] [Abstract][Full Text] [Related]
14. Dopamine D
Rivera A; Gago B; Suárez-Boomgaard D; Yoshitake T; Roales-Buján R; Valderrama-Carvajal A; Bilbao A; Medina-Luque J; Díaz-Cabiale Z; Craenenbroeck KV; Borroto-Escuela DO; Kehr J; Rodríguez de Fonseca F; Santín L; de la Calle A; Fuxe K
Addict Biol; 2017 Sep; 22(5):1232-1245. PubMed ID: 27212105
[TBL] [Abstract][Full Text] [Related]
15. Molecular neurological correlates of endorphinergic/dopaminergic mechanisms in reward circuitry linked to endorphinergic deficiency syndrome (EDS).
Blum K; Baron D; McLaughlin T; Gold MS
J Neurol Sci; 2020 Apr; 411():116733. PubMed ID: 32088516
[TBL] [Abstract][Full Text] [Related]
16. Actions of narcotics on brain dopamine metabolism and their relevance for "psychomotor" effects.
Kuschinsky K
Arzneimittelforschung; 1976 Apr; 26(4):563-7. PubMed ID: 8059
[TBL] [Abstract][Full Text] [Related]
17. The influence of drug class on reward in substance use disorders.
Jones JD; Arout CA; Luba R; Murugesan D; Madera G; Gorsuch L; Schusterman R; Martinez S
Pharmacol Biochem Behav; 2024 Jul; 240():173771. PubMed ID: 38670466
[TBL] [Abstract][Full Text] [Related]
18. Antireward, compulsivity, and addiction: seminal contributions of Dr. Athina Markou to motivational dysregulation in addiction.
Koob GF
Psychopharmacology (Berl); 2017 May; 234(9-10):1315-1332. PubMed ID: 28050629
[TBL] [Abstract][Full Text] [Related]
19. [Neurobiology of opioid dependence].
Scherbaum N; Bonnet U
Schmerz; 2018 Dec; 32(6):483-494. PubMed ID: 29946961
[TBL] [Abstract][Full Text] [Related]
20. Implication of dopaminergic projection from the ventral tegmental area to the anterior cingulate cortex in μ-opioid-induced place preference.
Narita M; Matsushima Y; Niikura K; Narita M; Takagi S; Nakahara K; Kurahashi K; Abe M; Saeki M; Asato M; Imai S; Ikeda K; Kuzumaki N; Suzuki T
Addict Biol; 2010 Oct; 15(4):434-47. PubMed ID: 20731628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
